- Cathie Wood’s Ark Invest trimmed stakes in five major tech names across its flagship ETF on Friday
- ARKG continued its biotech buying spree, adding positions in nine companies including CRISPR Therapeutics and Intellia
- Selling extended beyond technology, with ARKF shedding ARKB and DraftKings while ARKX exited Iridium Communications
Cathie Wood’s Ark Invest executed a broad portfolio reshuffle on Friday, selling positions in several high-profile technology and growth companies while adding to a diverse group of biotechnology stocks across its genomics-focused ETF. The selling was concentrated across multiple Ark funds rather than limited to one portfolio segment.
ARK Innovation ETF pared its stake in five prominent companies: SpaceX, AMD, Alphabet, Robinhood Markets, and Shopify. The trades extended beyond technology, as ARKF sold its position in the ARK 21Shares Bitcoin ETF and DraftKings.
Meanwhile, ARKG reduced positions in Personalis and CareDx, while ARKX sold Iridium Communications. The technology sales included both semiconductor and internet exposure, with AMD, Alphabet, and Shopify appearing among ARKK’s sell list.
However, the buying activity was heavily concentrated in ARKG, where the fund added positions across nine biotech companies rather than concentrating on a single stock. Purchases included gene-editing firms CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics.
Additional ARKG buying targeted Nurix Therapeutics, Guardant Health, Kymera Therapeutics, Compass Pathways, Alamar Biosciences, and Freenome. Meanwhile, ARKQ bought shares of Symbotic and Kodiak AI.
ARKG’s price closed up over 4% in Friday’s regular trading session and rose nearly 0.4% in after-hours trading. Despite the gains, retail sentiment on Stocktwits around ARKG trended bearish at the time of writing.
✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.
